Boston-based biotechnology company Life Biosciences has launched the first-in-human clinical trials of a pioneering “partial cellular reprogramming” technique designed to treat optic nerve damage caused by glaucoma and NAION. Based on previous genetic research, the therapy utilizes a modified virus to deliver three youth-restoring genes to retinal cells, aiming to reverse cellular aging while preserving their specialized functions. Addressing the critical risk of inducing cancer through uncontrolled cell division, the protocol incorporates a vital safety switch: the rejuvenating genes are only activated in the presence of the antibiotic doxycycline. The eye was strategically selected for these initial trials because its relative isolation minimizes the risk of systemic, life-threatening side effects. Involving up to 12 patients, this groundbreaking study serves as a crucial test not only for the potential restoration of vision but for the safety, viability, and future reputation of partial reprogramming as a broader anti-aging and regenerative medicine therapy.

A participant in a landmark clinical trial has been given a cellular-reprogramming treatment that aims to rejuvenate damaged cells in the eye.